![]() | A major contributor to this section appears to have a close connection with its subject. (May 2023) |
![]() | |
Company type | KGaA with Aktiengesellschaft as partner with unlimited liability |
---|---|
FWB: FME FWB: FMEA (ADR) OTC Pink Current: FMCQF NYSE: FMS (ADR) MDAX component (FME) | |
ISIN | DE0005785802 US3580291066 |
Industry | Health care |
Founded | 1996 |
Headquarters | Bad Homburg vor der Höhe, Germany |
Key people | Helen Giza (CEO, Chair of the management board and acting CFO) Dieter Schenk (Chairman of the supervisory board) |
Products | Dialysis products and services, Therapeutic Apheresis Products |
Revenue | €19.40 billion (2022) |
€1.51 billion (2022) | |
€0.67 billion (2022) | |
Total assets | €34,367 million (2021) |
Total equity | €13,979 million (2021) |
Owner | Fresenius (32%) |
Number of employees | 128,000 (2022)[1] |
Website | www |
Footnotes / references [2][3] |
Fresenius Medical Care AG & Co. KGaA is a German healthcare company which provides kidney dialysis services through a network of 4,171 outpatient dialysis centers, serving 345,425 patients.[3] The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo dialysis 3 times per week for the rest of their lives.
With a global headquarters in Bad Homburg vor der Höhe, Germany, and a North American headquarters in Waltham, Massachusetts, it has a 38% market share of the dialysis market in the United States. It also operates 42 production sites, the largest of which are in the U.S., Germany, and Japan.[4]
The company is 32% owned by Fresenius[5] and, as of 2020, generates around 50% of the group's revenue.[6]
The company is on the Best Employers List published by Forbes.[7]